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Introduction 
 
High meat intake has been demonstrated to be 
associated with an increased risk of colorectal 
adenoma (CRA) in some [1, 2] but not all stud-
ies [3, 4]. In addition, a systematic review of the 
epidemiological studies has suggested that high 
consumption of red and processed meat is con-
vincingly associated with an increased risk of 
colorectal cancer (CRC) [5]. One factor possibly 
explaining these associations is the observation 
that potent chemical carcinogens such as het-
erocyclic aromatic amines (HCAs) are generated 
when meat is cooked at high temperature [6, 7]. 
For HCAs to be carcinogenic, they must be acti-
vated by enzymes. In an initial step, they are N-
hydroxylated by cytochrome P450 1A2 
(CYP1A2), followed by conjugation of the result-
ing N-hydroxyl group by N-acetyltransferase 
(NAT) or sulfotransferase (SULT). In addition to 
bioactivation by NAT or SULT, enzymes such as 
UDP-glucuronyltransferases or glutathione S-
transferases (GST) contribute to the detoxifica-
tion of HCAs [8].  
 
These enzymes are encoded by genes that are 
highly polymorphic in humans, thus, leading to 
interindividual differences in enzyme activities 
and inducibility. Such differences in bioactivat-
ing and detoxifying capacity may lead to varia-
tion in adenoma and cancer risk between indi-
viduals. Thus, polymorphisms might be used to 
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identify high risk persons [9, 10].  
 
To date, only 5 case-control studies [4, 9, 11-
13] have evaluated the associations between 
the polymorphisms in genes analyzed in the 
present article and CRA risk. A greater number 
of studies tried to clarify the relevance of such 
polymorphisms for colorectal cancer (e.g., [11, 
14-16] and a meta-analysis [17]. Adenomas are 
considered to be precursor lesions that may 
develop to CRC, but risk modulation by polymor-
phisms may differ between colorectal adenoma 
and carcinoma, respectively. Overall, the evi-
dence for main effects of single-nucleotide poly-
morphisms (SNPs) related to both colorectal 
adenoma and cancer is sparse and for the for-
mer based on only a few studies. 
 
In the context of a case-control study nested 
within the Heidelberg cohort of the European 
Prospective Investigation into Cancer and Nutri-
tion (EPIC) study, we explored the association of 
polymorphisms in HCA metabolism-related 
genes with risk of colorectal adenomas. Interac-
tions with heterocyclic amine intake, meat in-
take or smoking were not part of the present 
analysis. 
 
Materials and methods 
 
Study population 
 
The study population consists of participants of 
the EPIC-Heidelberg cohort. EPIC-Heidelberg is 
part of the European Prospective Investigation 
into Cancer and Nutrition (EPIC), a European-
wide cohort study with more than 500,000 par-
ticipants. Participants in Heidelberg were re-
cruited at random in a predefined age range 
from the general population in Heidelberg, Ger-
many, and surrounding communities between 
1994 and 1998. At recruitment, women were 
35-65 and men 40-65 years old. The final co-
hort consists of 25,540 participants (38% of 
those originally invited) [18].  
 
At the baseline examination, questionnaires and 
interviews were used to assess information on 
diet, lifestyle, education and medical history. 
Anthropometric data were assessed in the study 
center, where also a 30-ml blood sample was 
taken from 95.8% of the study participants [19]. 
Blood samples were aliquotted into 0.5 mL 
straws of serum, plasma, buffy coat, and eryth-
rocytes, respectively, and stored in liquid nitro-
gen at -196°C.  
 
Since the recruitment of the study participants, 
three rounds of follow-up have been conducted 
in the EPIC-Heidelberg cohort. The aim of the 
follow-up is to collect, among others, informa-
tion on the occurrence of major chronic dis-
eases. Within these follow-ups, the study partici-
pants were asked to report the diagnosis of be-
nign tumors, such as colorectal polyps. After 
three follow-ups (between September 1997 and 
2007), 960 participants had declared the diag-
nosis of a colorectal polyp. Colorectal polyps 
reported by the study participants were verified 
by a trained physician by means of medical re-
cords. The second version of the International 
Classification of Diseases for Oncology was ap-
plied to code incident adenoma cases. Through 
verification, 536 were identified as incident co-
lorectal adenomas and 171 as hyperplastic pol-
yps.  
 
After exclusion of prevalent and incident cases 
of cancer (except for non-melanoma skin can-
cer), myocardial infarction and stroke, 444 
cases of colorectal adenomas for which blood 
samples were available were included in the 
study. Two controls per case were selected from 
subjects who had reported a negative colono-
scopy; from the group of eligible controls we 
excluded prevalent or incident cancer cases 
(besides non-melanoma skin cancer), subjects 
who reported prevalent colorectal adenoma, 
prevalent or incident hyperplastic polyps, and 
subjects with missing blood samples. Cases and 
controls were matched by sex, age (+/- 1 year), 
and year of recruitment (+/- 0.5 years). Controls 
had to be alive at the time the matched case 
was diagnosed with adenomas.  
 
Of the 1332 participants included in our study, 
50 (3.7%) were excluded because genotyping 
failed and 14 individuals of incomplete case 
sets (i.e., controls without corresponding case 
or cases without controls). The analytical data-
set included 428 cases and 828 controls.  
 
All study participants signed a consent form and 
the ethics committee of the Heidelberg Medical 
School approved the study. 
 
Laboratory analyses 
 
Genomic DNA was extracted from buffy coat 
with FlexiGene kit (Qiagen) in accordance with 
Genetic polymorphisms and risk of colorectal adenoma  
 
 
98                                                                                                Int J Mol Epidemiol Genet 2012:3(2):96-106 
the manufacturer's instructions. DNA was 
stored at 4°C until use. Genotyping for polymor-
phisms of the genes NAT1 (C1095A, rs15561), 
NAT2  (T341C, rs1801280; G590A, 
rs1799930), GSTA1 (G-52A, rs3957357; which 
is fully linked to C-69T), SULT1A1 (G638A, 
rs9282861), CYP1A2 (A-164C, rs762551), UG-
T1A7 (T387G, rs17868323; G392A, 
rs17868324; T622C, rs11692021), UGT1A9 (A
(T)9/10AT, rs3832043), and GSTP1 (A313G, 
rs1695), were done as multiplex on the MassAr-
ray system (Sequenom) applying the iPLEX 
method and matrix-assisted laser desorption/
ionization-time-of-flight mass spectrometry for 
analyte detection. The analysis was carried out 
by Bioglobe (Hamburg, Germany). All duplicated 
samples (quality-control repeats of 8% of the 
samples) to verify interexperimental reproduci-
bility and accuracy delivered concordant geno-
type results by >95%. A LightCycler 480 (Roche) 
was used to determine two more polymor-
phisms in NAT1 (T1088A, rs1057126, G560A, 
rs4986782) and one more in NAT2 (G857A, 
rs1799931) with real time PCR and melting 
curve analysis using hybridization probes. Deter-
mination was done in triplicate and a SD of 
>10% led to repeated analysis. Five percent of 
the samples were repeated for quality-control 
reasons and concordance of the assigned geno-
types was >95%. All laboratory analyses were 
carried out with the laboratory personnel 
blinded to the case-control status. 
 
Statistical analysis 
 
Three SNPs in NAT1 [T1088A (rs1057126), 
G560A (rs4986782), and C1095A (rs15561)] 
were used to identify carriers of the NAT1*4 
(wild type) allele and the NAT1*10 (T1088A and 
C1095A), NAT1*11 (C1095A) and NAT1*14 
allele (T1088A, C1095A and G560A). 
 
To distinguish carriers of the NAT1*10 allele 
from the NAT1*14 allele, we used the G560A 
polymorphism. Other genotypes were not ac-
counted for in our study. We determined 3 SNPs 
in NAT2 [T341C (NAT2*5) (rs1801280), G590A 
(NAT2*6) (rs179930), and G857A (NAT2*7) 
(rs1799931)], which were used to construct 
three phenotypes: Fast acetylators were defined 
as carriers of two NAT2*4 alleles (no polymor-
phisms at any of the three sites); intermediate 
acetylators were carriers of one NAT2*4 allele 
and one mutant allele, and slow acetylators had 
no NAT2*4 allele. GSTA1 activity was defined 
as normal when having GG or GA allele at 
rs3957357; AA has decreased activity [20]. 
Carriers of the GG and GA alleles of rs9282861 
(SULT1A1) were defined as having normal en-
zyme activity, the AA alleles as having de-
creased activity [21]. Homozygous carriers of 
the A allele in rs762551 (CYP1A2) were classi-
fied as having normal enzyme activity, carriers 
of the GA or GG alleles as having enhanced ac-
tivity [22]. Three SNPs in UGT1A7 [T387G 
(rs17868323), which is related to the 
Asp129Lys amino acid change, G392A 
(rs17868324; related to Arg131Lys), and 
T622C (rs11692021; related to Trp208Arg)] 
were used to identify carriers of the UGT1A7*1 
allele (wild type), the allele UGT1A7*2 
(Asp129Lys & Arg131Lys), the allele UGT1A7*3 
(Asp129Lys, Arg131Lys & Trp208Arg) allele 
UGT1A7*4 allele (Trp208Arg). These four al-
leles were used to determine phenotypes with 
low, intermediate, and high enzyme activity: 
high (*1/*1, *1/*2, *2/*2), intermediate (*1/
*3, *1/*4, , *2/*3), and low (*3/*3, *3/*4, 
*4/*4) [23]. 
 
For UGT1A9, individuals with deletions at 
rs3832043 (i.e., A(T)9AT) were classified as hav-
ing normal activity, whereas DEL/T or TT (i.e., A
(T)10AT) variants lead to enhanced activity [24]. 
 
Genotype frequencies for the selected polymor-
phisms were computed and deviations from 
Hardy-Weinberg equilibrium (HWE) were deter-
mined by χ2 test. Conditional logistic regression 
was used to examine the associations between 
genotypes of the above mentioned genes and 
colorectal adenomas stratified by matched case 
set. Tests for linear trend (additive genotype 
models) were also employed. Similarly, we ex-
amined the associations between phenotypes 
and adenoma risk. In most cases, carriers of the 
homozygous common allele were used as refer-
ence category; exceptions were UGT1A7_129 
and UGT1A7_131. All statistical analyses were 
conducted using SAS version 9.2 (SAS Institute, 
Inc., Cary, NC). 
 
Results 
 
Baseline characteristics of the participants in 
this nested case-control study including ade-
noma size and location and the main risk fac-
tors are summarized in Table 1. Cases with co-
lorectal adenoma and controls did not differ by 
age at recruitment, sex and year of recruitment 
Genetic polymorphisms and risk of colorectal adenoma  
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(matching factors). Cases were more likely to 
have a family history of colorectal cancer, to be 
current smokers, to drink more alcohol and to 
have a higher intake of processed meat. They 
less often had a university degree. There were 
no differences in mean BMI and intake of die-
tary fiber and energy. 
 
All cases and controls were genotyped for poly-
morphisms in eight genes of phase I and phase 
II carcinogen-metabolizing enzymes being of 
importance in the activation or detoxification of 
HCAs. The corresponding genotype frequencies 
of NAT1, NAT2, GSTA1, SULT1A1, CYP1A2, UG-
T1A7, UGT1A9, GSTP1 in case and control sub-
jects are shown in Table 2. All genotype distribu-
tions in the control group were in Hardy-
Weinberg equilibrium with the exception of UG-
T1A7_129, UGT1A7_131 and UGT1A9. For 
NAT1_560 and NAT2_857 the equilibrium could 
not be tested because the number of subjects 
was less than five in at least one category of the 
chi-squared test.  
 
In Tables 2 and 3, the associations between 
genetic variants and derived phenotypes and 
colorectal adenoma risk are summarized.  
 
A significantly decreased risk was observed be-
tween colorectal adenoma risk and NAT1_1095 
(rs15561) CA versus CC genotypes; with each 
rare allele, risk decreased by 20% (95% CI = 
0.65-0.97). A similar result was obtained per A 
allele of rs1057126 (NAT1) (OR = 0.81; 95% CI 
= 0.65-0.99). Genetic polymorphisms related to 
NAT1_1088 (rs1057126) and NAT1_560 
(rs4986782) did not reveal statistically signifi-
cant associations with colorectal adenoma 
Table 1. Baseline characteristics of colorectal adenoma cases and controls (with a negative colono-
scopy) in the EPIC-Heidelberg study. 
  Controls Cases 
  N Percent N Percent 
Adenoma size         
   ≤ 1cm     178 41.6 
   > 1 cm     140 32.7 
   Missing     110 25.7 
Adenoma location*         
   Right colon & transversum     118 27.6 
   Left colon     155 36.2 
   Rectum     93 21.7 
   Missing     19 4.4 
          
Sex         
   Male 540 65.2 279 65.2 
   Female 288 34.8 149 34.8 
Education, university degree 261 31.5 125 29.2 
Smoking status         
   Never 328 39.6 145 33.9 
   Former 378 45.7 196 45.8 
   Current 122 14.7 87 20.3 
Family history of colorectal cancer 92 11.1 71 16.6 
          
  Mean std Mean std 
Age at recruitment (years) 54.6 6.2 54.5 6.2 
Age at diagnosis (years)     60.3 6.6 
BMI (kg/m2) 26.4 3.5 26.4 3.4 
Total energy (kcal/d) 1978 638 2011 697 
Alcohol (g/d) 20.4 23.7 24.4 27.3 
Dietary fiber (g/d) 20.5 7.2 20.0 6.9 
Processed meat (g/d) 51.5 40.4 56.2 42.5 
*The colon was divided based on ICD-10 into right colon & transversum (C180, C181, C182, C183, C184, C1841, C1842, C1843, 
and C185), left colon (C186 and C187), and rectum (C199, C209, C2091, C2092, and C2093). 
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 Table 2. Association between polymorphisms in HCA-metabolizing genes and risk of colorectal adenomas in EPIC-Heidelberg 
SNP rs number allele cases controls OR CI 
NAT1_1088 rs1057126 TT 278 501 1 Ref. 
NAT1_1088 rs1057126 TA 121 264 0.82 (0.63, 1.06) 
NAT1_1088 rs1057126 AA 16 44 0.62 (0.34, 1.12) 
Per allele         0.81 (0.65, 0.99) 
HWE*       0.24     
NAT1_560 rs4986782 GG 396 748 1 Ref. 
NAT1_560 rs4986782 GA 15 39 0.73 (0.40, 1.34) 
NAT1_560 rs4986782 AA 0 0 -- -- 
HWE*       --**     
NAT1_1095 rs15561 CC 256 436 1 Ref. 
NAT1_1095 rs15561 CA 144 328 0.74 (0.58, 0.96) 
NAT1_1095 rs15561 AA 26 60 0.72 (0.44, 1.17) 
Per allele         0.80 (0.65, 0.97) 
HWE*       0.88     
NAT2_341 rs1801280 TT 127 276 1 Ref. 
NAT2_341 rs1801280 CT 214 396 1.19 (0.90, 1.57) 
NAT2_341 rs1801280 CC 86 153 1.25 (0.89, 1.78) 
Per allele         1.13 (0.95, 1.34) 
HWE*       0.60     
NAT2_590 rs1799930 GG 211 418 1 Ref. 
NAT2_590 rs1799930 GA 177 337 1.03 (0.80, 1.32) 
NAT2_590 rs1799930 AA 39 71 1.04 (0.67, 1.60) 
Per allele         1.02 (0.85, 1.23) 
HWE*       0.79     
NAT2_857 rs1799931 GG 387 745 1 Ref. 
NAT2_857 rs1799931 GA 24 44 1.10 (0.66, 1.83) 
NAT2_857 rs1799931 AA 0 1 -- -- 
HWE*       --**     
GSTA1 rs3957357 GG 140 256 1 Ref. 
GSTA1 rs3957357 GA 222 395 1.01 (0.78, 1.32) 
GSTA1 rs3957357 AA 66 175 0.68 (0.48, 0.97) 
Per allele         0.85 (0.72, 1.01) 
HWE*       0.32     
SULT1A1 rs9282861 GG 183 389 1 Ref. 
SULT1A1 rs9282861 AG 193 354 1.15 (0.90, 1.48) 
SULT1A1 rs9282861 AA 48 76 1.31 (0.88, 1.96) 
Per allele         1.15 (0.96, 1.37) 
HWE*       0.72     
CYP1A2 rs762551 AA 207 403 1 Ref. 
CYP1A2 rs762551 CA 171 348 0.97 (0.75, 1.24) 
CYP1A2 rs762551 CC 46 70 1.24 (0.82, 1.87) 
Per allele         1.06 (0.88, 1.26) 
HWE*       0.67     
UGT1A7_129 rs17868323 GG 161 305 1 Ref. 
UGT1A7_129 rs17868323 GT 202 425 0.90 (0.70, 1.16) 
UGT1A7_129 rs17868323 TT 62 93 1.23 (0.85, 1.78) 
Per allele         1.05 (0.88, 1.26) 
HWE*       0.002     
UGT1A7_131 rs17868324 AA 161 305 1 Ref. 
UGT1A7_131 rs17868324 GA 203 425 0.91 (0.52, 1.05) 
UGT1A7_131 rs17868324 GG 62 93 1.24 (0.56, 1.16) 
Per allele         1.06 (0.89, 1.26) 
HWE*       0.002     
UGT1A7_208 rs11692021 TT 153 318 1 Ref. 
UGT1A7_208 rs11692021 CT 210 396 1.11 (0.86, 1.43) 
UGT1A7_208 rs11692021 CC 65 114 1.18 (0.82, 1.69) 
Per allele         1.09 (0.92, 1.29) 
HWE*       0.60     
UGT1A9 rs3832043 DEL 158 306 1 Ref. 
UGT1A9 rs3832043 T/DEL 206 428 0.94 (0.73, 1.21) 
UGT1A9 rs3832043 TT 62 91 1.29 (0.89, 1.86) 
Per allele         1.08 (0.91, 1.29) 
HWE*       0.001     
GSTP1 rs1695 AA 196 365 1 Ref. 
GSTP1 rs1695 GA 182 359 0.93 (0.72, 1.20) 
GSTP1 rs1695 GG 49 99 0.91 (0.62, 1.34) 
Per allele         0.95 (0.80, 1.13) 
HWE*       0.46     
*P value of χ2 test for deviation from HWE in controls; ** not computed because n<5 in at least one category 
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(Table 2). For NAT1 phenotypes derived from 
these polymorphisms (Table 3), adenoma risk 
decreased, although results were not statisti-
cally significant. 
 
No association could be established between 
adenoma risk and single polymorphisms in 
NAT2. However, a statistically significant inverse 
association (OR = 0.75; 95% CI = 0.85-0.97) 
was observed for the combined alleles encoding 
for enzymes with medium versus slow activity 
(Table 3). For fast metabolizers (versus slow 
metabolizers) the risk estimate was even lower 
but did not reach statistical significance (OR = 
0.65; 95% CI = 0.35-1.20).  
 
Homozygous carriers of the A allele of 
rs3957357 (GSTA1), i.e., those with a de-
creased enzyme activity, showed a significantly 
decreased risk of colorectal adenoma with an 
OR of 0.68 (95% CI = 0.50-0.92; AA versus GG/
GA). 
 
Genetic polymorphisms in CYP1A2 (rs762551), 
GSTP1 (rs1695), SULT1A1 (rs9282861), UG-
T1A7 (rs11692021), UGT1A7 (rs17868323), 
UGT1A7 (1786324), and UGT1A9 (rs3832043) 
genes did not reveal any statistically significant 
association with colorectal adenoma risk (Table 
2). This was also true for combinations of geno-
types in these genes, encoding for enhanced or 
impaired enzymatic activity versus normal activ-
ity (Table 3). 
 
Discussion 
 
Polymorphisms in genes encoding for enzymes 
in the metabolic activation and detoxification of 
HCA are believed to result in variation in me-
tabolism, potentially affecting colorectal ade-
noma and cancer risk [9]. In a nested case-
control study, we investigated the role of poly-
morphisms in the following HCA metabolism-
related genes in the development of colorectal 
adenomas. By this we add new findings to the 
very limited or missing results of previous stud-
ies on colorectal adenomas. Interactions with 
heterocyclic amine intake, meat intake or smok-
ing will be presented in another article.  
 
NAT1, NAT2 
 
N-acetyltransferase (NAT) enzymes are respon-
sible for metabolizing HCAs via N-acetylation 
Table 3. Association between phenotypes of HCA-metabolizing genes and risk of colorectal adenomas in 
EPIC-Heidelberg. 
Gene Phenotype/enzyme activity cases controls OR CI 
NAT1 *4/*4 239 411 1 Ref. 
NAT1 *10/other 96 210 0.76 (0.56, 1.03) 
NAT1 *10/*10 11 34 0.52 (0.26, 1.06) 
NAT1 Other 53 121 0.75 (0.52, 1.08) 
NAT2 Slow 248 421 1 Ref. 
NAT2 Medium 146 328 0.75 (0.58, 0.97) 
NAT2 Fast 16 41 0.65 (0.35, 1.20) 
GSTA1 Normal (GG&GA) 362 651 1 Ref. 
GSTA1 Decreased (AA) 66 175 0.68 (0.50, 0.92) 
SULT1A1 Normal (GG&GA) 376 743 1 Ref. 
SULT1A1 Decreased (AA) 48 76 1.22 (0.84, 1.78) 
CYP1A2 Normal (AA) 207 403 1 Ref. 
CYP1A2 Enhanced (CC&CA) 217 418 1.01 (0.80, 1.28) 
UGT1A7 High 153 318 1 Ref. 
UGT1A7 Medium 207 391 1.09 (0.84, 1.41) 
UGT1A7 Low 65 114 1.16 (0.81, 1.67) 
UGT1A9 Normal (Del) 158 306 1 Ref. 
UGT1A9 Enhanced (Del/T & TT) 268 519 1.00 (0.79, 1.27) 
NAT1: 5 subjects with missing information 
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(detoxification) or via O-acetylation (activation), 
possibly depending on HCA concentration. Of 
the two polymorphic NAT enzymes, the NAT2 
genotype-phenotype relationship is well-
established, whereas for NAT1 it remains rather 
unclear [8, 25-27].  
 
In the present analysis, a significant inverse 
association was observed between colorectal 
adenoma risk and the NAT1 (rs15561) CA ver-
sus CC genotype whereas for NAT1 phenotypes, 
no significant results were observed. Per A allele 
of rs1057126 (NAT1) risk decreased statisti-
cally significantly by nearly 20% With respect to 
NAT2, a statistically significant inverse associa-
tion was observed for the combined alleles en-
coding for medium versus slow metabolizers; 
only few cases and controls were classified as 
fast metabolizers. These results are in contrast 
to two previous case-control studies on CRA [4, 
12]. In these studies, rapid acetylator NAT1 
genotypes were associated with a significantly 
elevated risk of colorectal adenomas compared 
to slow acetylator genotypes. There is no clear 
consensus for imputing NAT1 phenotypes. 
Therefore, our and these two studies differ from 
what is considered as slow, intermediate and 
rapid alleles. The study by Tiemersma et al. [4] 
grouped NAT1 acetylators as follows: slow (at 
least 1 *11 allele), normal (no *10 or *11 al-
leles) and fast (at least 1 *10, no *11 allele). 
Shin et al. [12] considered any participants pos-
sessing slow alleles (NAT1*14, *15, *17, *19, 
*22) to be a slow acetylators, any participants 
homozygous for rapid alleles (NAT1*10, *11) or 
in combination with a NAT1*3 and *4 allele to 
be a rapid acetylator, and all others as interme-
diate acetylators. In the same two studies, NAT2 
polymorphisms did not show any significant 
association. Concerning colorectal cancer risk, a 
meta-analysis including three studies on NAT1 
and 10 studies on NAT2 observed a non-
significant association with colorectal cancer 
risk for NAT1*10 (OR = 1.25; 95% CI = 0.96–
1.63), and no association for the NAT2-rapid 
acetylator genotype [28]. 
 
GSTA1, GSTP1 
 
GSTs catalyze reactions between glutathione 
and lipophilic compounds with electrophilic cen-
tres, resulting in neutralisation of toxic com-
pounds, etc. Among others, GSTA1 variants 
(GSTA1*B) and the Ile105Val variant of GSTP1 
might be associated with decreased enzymatic 
activities [17].  
 
In the present analysis, a significantly de-
creased colorectal adenoma risk was observed 
for AA versus GG genotypes in rs3957357 
(GSTA1). The association remained significant 
for AA versus the combined GG and GA geno-
types, such that participants with decreased 
activity had a lower adenoma risk compared 
with those who have enzymes with normal activ-
ity. These results seem to be in contradiction 
with the role of GSTA in the detoxification proc-
ess of carcinogens. To our knowledge, no com-
parable studies in CRA cases and controls have 
been published so far.  
 
In a study with similar results for gastric cancer 
[29], the authors pointed out that lower expres-
sion of the GSTA1 protein due to the GSTA1 
polymorphism may be compensated by an over-
expression of the GSTA2 enzyme [30]. In a meta
-analysis [17] including four case-control stud-
ies, no significant associations were demon-
strated regarding heterozygous or homozygous 
GSTA1 status and CRC risk.  
 
Moreover, in the present study, no significant 
associations between GSTP1 Ile105Val 
(rs1695) and CRA risk were detected. These 
findings are in accordance with the results from 
a case-control study by Northwood et al. [13], 
the only other survey on this topic published so 
far.  
 
In relation to CRC risk in the already mentioned 
meta-analysis by Economopoulous et al. [17] 
(based on nineteen case-control studies), no 
overall statistically significant associations be-
tween GSTP1 Ile105Val (rs1695) and CRC risk 
were detected neither in Caucasians nor in Chi-
nese people.  
 
CYP1A2 
 
The phase I enzymes CYP1A1 and CYP1A2 play 
a role in HCA activation, and the resulting N-
hydroxy-HCA metabolites can directly react with 
DNA to form covalent adducts. Of the polymor-
phic CYP1A2 alleles, besides others, 
CYP1A2*1F has been associated with en-
hanced inducibility of expression and enhanced 
enzyme activity [8, 19].  
 
In the present study, no association between 
the CYP1A2*1F polymorphism and colorectal 
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adenoma was observed. This result is in accor-
dance with the null findings of two other studies 
on colorectal adenoma with 2495 and 604 par-
ticipants, respectively [12, 13]. A small survey 
of 94 individuals [9] on the other hand, found a 
statistically significant direct association be-
tween the CYP1A2*1F polymorphism CC & CA 
vs. AA and colorectal adenoma risk, but the high
-risk group (n = 38) included not only CRA cases 
but also individuals with carcinoma in situ. 
 
In relation to CRC risk, one study showed no 
association with CYP1A2*1F polymorphism 
[31], another study suggested an increased risk 
for CRC among those with non-AA-genotypes 
[32]. In a Japanese study, a negative associa-
tion for the CC genotype versus AA was seen, 
but the association disappeared for the com-
bined CC and CA genotypes [16]. All of them 
were case-control studies. 
 
UGT1A7, UGT1A9 
 
UDP-glucoronyltransferases (UGTs) catalyze the 
glucuronidation and elimination of various com-
pounds, including HCAs [8]. Of these, the UG-
T1A7 isoform is mainly expressed in the GI tract. 
In relation to UGT1A9 polymorphisms, it was 
observed [24] that the transcriptional activity of 
the promoter region containing A(T)10AT was 
increased by 2.6-fold compared to that of A(T)
9AT, suggesting that the UGT1A9 protein level in 
vivo is increased in subjects carrying the variant 
allele.  
 
In this study, UGT1A7 (rs11692021, 
rs17868323, rs1786324) genes did not reveal 
any statistically significant association with colo-
rectal adenoma. No previous epidemiological 
study has examined UGT1A7 alleles in relation 
to colorectal adenoma risk. With respect to CRC, 
one case-control study [33] observed a signifi-
cant positive association and another [14] 
found a statistically significant association only 
after combination of all variant alleles. Further-
more, an increased risk was shown for patients 
with distal colon cancer who had the variant 
UGT1A7 alleles compared with patients who 
had the most common alleles (OR = 3.0; 95% CI 
= 1.5-6.2). 
 
In the present study, a genetic polymorphism 
related to UGT1A9 (rs3832043), leading to en-
hanced enzyme activity, did not reveal any sta-
tistically significant associations with colorectal 
adenoma. To our knowledge, this is the first 
study to evaluate this association. 
 
SULT1A1 
 
SULTs are involved both in activation and de-
toxification of HCAs [8]. Therefore, it is difficult 
to predict the effect of polymorphic enzymes on 
CRA risk following exposure to HCAs. SULT1A1, 
a member of the SULT gene family, is polymor-
phic with the common allele, SULT1A1*2, 
where G is changed to A at nucleotide 638. Car-
riers of the GG and GA allele of SULT1A1 are 
defined as having normal enzyme activity, the 
AA allele as having decreased activity [21]. 
 
In the present study, genetic polymorphisms 
related to SULT1A1 (rs9282861) did not reveal 
any statistically significant associations with 
colorectal adenoma. This is also true for the AA 
genotype compared with the combined group of 
GG and AG genotypes. In the already mentioned 
Dutch case-control study [4], significant results 
were only found for interaction between 
SULT1A1 and GSTT1 genes. In an additional 
study [11], individuals with SULT1A1 638AA 
genotype and NAT1 and NAT2 intermediate/fast 
phenotypes had a 3.5-fold increased risk of co-
lorectal adenoma (95% CI = 1.2-10.3) com-
pared with individuals with SULT1A1 638GG 
genotype and NAT1 and NAT2 slow phenotypes.  
 
The absence of a main effect of SULT1A1 geno-
type on colorectal adenoma in the present study 
is in line with findings from several previous 
case-control studies on colorectal cancer [34-
40]. In contrast, in a Swedish case-control study 
a significantly increased risk of CRC was ob-
served for SULT1A1*2 carriers, based on 109 
patients [41].  
 
Conclusions 
 
Out of the polymorphisms in HCA metabolism-
related genes evaluated in the present study 
only a few were associated with colorectal ade-
noma risk. These findings might be due to the 
complex relationship between genotype and 
phenotype of these enzymes, especially for 
NAT1. Besides the effect of genetic constella-
tion, the enzymatic activity can be influenced by 
environmental factors such as smoking and diet 
[14], but also by gene–gene interactions [42]. 
On the other hand, in the absence of exposure 
to a genotoxin, the genetic polymorphism is not 
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necessarily being expected to be manifested as 
a risk factor. Since the same enzymes are in-
volved both in activation and in detoxification of 
HCAs and the enzymes possess overlapping 
substrate-specificity, it is difficult to predict the 
consequences of these enzymes in individual 
susceptibility. Even though we investigated a 
considerable number of genes coding for phase 
I and II enzymes, additional enzymes and poly-
morphisms, respectively, are involved in the bio-
activation and detoxification of HCAs. Further-
more, the location of the adenoma in the colon 
or rectum might be of importance.  
 
In addition, there are issues of chance, bias and 
confounding to consider. The number of hy-
potheses tested in the present study urges cau-
tion in the interpretation of significant results.  
 
Cases and controls were adequately matched 
by age, sex and year of recruitment, but not by 
family history of CRC (data not available). In-
cluding only participants with a negative colono-
scopy in our control group might have affected 
the results, because this subgroup might have 
been in need of a colonoscopy and, thus, might 
not have been completely healthy. On the other 
hand, this subgroup might have been more 
health-conscious and, thus, more likely to par-
ticipate in the colorectal screening program. 
This choice of controls is nevertheless justified 
by the fact that most individuals do not know 
that they have colorectal adenomas [43]. The 
agreement of allele frequencies detected in 
control subjects with published data [12] gives 
reassurance that no selection of genotypes oc-
curred by the definition of the control group. 
With respect to the outcome, all self-reported 
diagnoses were medically confirmed, allowing 
the separation of adenoma cases from other 
types of colorectal polyps. 
 
In conclusion, our findings suggest that some 
polymorphisms in HCA metabolism-related 
genes are associated with a decreased risk of 
colorectal adenoma, which could ultimately de-
velop to CRCs. These include polymorphisms in 
NAT1, NAT2, and GSTA1.  
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